Two New Doses of Dulaglutide (Trulicity) for Diabetes

Date: October 19, 2020
Issue #: 
1609Summary: 
The FDA has approved two additional doses (3 mg
and 4.5 mg) of the glucagon-like peptide-1 (GLP-1)
receptor agonist dulaglutide (Trulicity– Lilly) for
treatment of type 2 diabetes in adults. Dulaglutide has
been available in 0.75- and 1.5-mg doses for years.

Source: The Medical Letter - October 9, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research